If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Shield Therapeutics plus Chris Bailey on 3 large caps and John Meyer on 3 small resource stocks
Carl Sterritt, Chief Executive Officer of Shield Therapeutics (STX) discusses progress on Feraccru®, their lead drug and a big milestone which could occur this month.
hield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.
Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com
Chris Bailey founder of Financial Orbit covers:
Persimmon (PSN)
Assocaited British Foods (ABF)
Sainsbury's (SBRY)
(Interview starts at 11 minutes 10 seconds)
John Meyer, Mining analyst and partner at SP Angel talks about:
Arc Minerals (ARCM)
Keras Resources (KRS)
Bushveld Minerals (BMN)
(Interview starts at 28 minutes 27 seconds)